Evaluation of Contraceptive Efficacy and Cycle Control of a Transdermal Contraceptive Patch vs an Oral Contraceptive<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Marie‐Claude Audet

JAMA · 2001 · 336 citations · 10 references

Concepts

TL;DR

Oral contraceptive pills are effective, but poor compliance increases pregnancy rates during treatment. The study aimed to compare contraceptive efficacy, cycle control, compliance, and safety between a transdermal contraceptive patch and an oral contraceptive. A randomized, open‑label, parallel‑group trial enrolled 1,417 women, assigning them to a transdermal patch (three consecutive 7‑day patches followed by a patch‑free week) or an oral contraceptive for 6 or 13 cycles, with overall and method‑failure Pearl Indexes and life‑table pregnancy probabilities as primary outcomes. The patch showed numerically lower Pearl Indexes (1.24 vs 2.18) but the difference was not significant; it had higher breakthrough bleeding in the first two cycles, higher perfect‑cycle compliance (88.2% vs 77.7%), only 1.8% detachment, and more application‑site reactions, yet overall efficacy and safety were comparable to the oral contraceptive.

Abstract

ContextOral contraceptive (OC) pills are effective, but poor compliance increases rates of pregnancy during treatment.ObjectiveTo compare the contraceptive efficacy, cycle control, compliance, and safety of a transdermal contraceptive patch and an OC.DesignRandomized, open-label, parallel-group trial conducted October 1997 to June 1999.SettingForty-five clinics in the United States and Canada.ParticipantsA total of 1417 healthy adult women of child-bearing potential.InterventionsParticipants were randomly assigned to receive a transdermal contraceptive patch (n = 812) vs an OC (n = 605) for 6 or 13 cycles. Patch treatment consisted of application of 3 consecutive 7-day patches followed by 1 patch-free week.Main Outcome MeasuresOverall and method-failure Pearl Indexes (number of pregnancies/100 person-years of use) and life-table estimates of the probability of pregnancy were calculated. Cycle control, compliance, patch adhesion, and adverse events were also assessed.ResultsOverall and method-failure Pearl Indexes were numerically lower with the patch (1.24 and 0.99, respectively) vs the OC (2.18 and 1.25, respectively); this difference was not statistically significant (P = .57 and .80, respectively). The incidence of breakthrough bleeding and/or spotting was significantly higher only in the first 2 cycles in the patch group, but the incidence of breakthrough bleeding alone was comparable between treatments in all cycles. The mean proportion of participants' cycles with perfect compliance was 88.2% (811 total participants, 5141 total cycles) with the patch and 77.7% (605 total participants, 4134 total cycles) with the OC (P < .001). Only 1.8% (300/16 673) of patches completely detached. Both treatments were similarly well tolerated; however, application site reactions, breast discomfort, and dysmenorrhea were significantly more common in the patch group.ConclusionThe contraceptive patch is comparable to a combination OC in contraceptive efficacy and cycle control. Compliance was better with the weekly contraceptive patch than with the OC.

References

10